Natera

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Natera reports robust Q4 results, eyes growth in genetic testing

Natera's Q4 2022 performance reflects strong growth in tests and revenues, particularly in oncology, setting the stage for future success.
The company's strategic milestones, new board appointment, and focus on clinical business growth highlight its resilience and market leadership.
While facing challenges in cost management and market competition, Natera has opportunities to leverage positive industry trends and policy changes for sustained growth.

Natera posts strong Q1 results, focuses on clinical differentiation

Natera's Q1 earnings call highlighted robust financials, strategic focus on clinical differentiation, and efforts to improve margins through ASP and COGS projects. Despite challenges with ASP and gross margins, the company remains optimistic about its trajectory and growth opportunities in women's health and organ health.

Natera reports stellar Q2 results, eyes growth amid regulatory changes

Natera delivered a strong Q2 performance with robust revenue growth, improved margins, and strategic advancements across oncology, women's health, and organ health segments.
The company showcased strengths in clinical utility, peer-reviewed publications, and litigation victories, while also addressing challenges like pricing pressures and regulatory changes.
Opportunities lie in expanding market reach through ACOG meetings, commercial coverage enhancements, and leveraging competitor exits for growth in carrier testing business.
Overall, Natera's revised guidance, financial outperformance, and focus on innovation position the company for continued success and market leadership in the genomics space.

Natera (NTRA) reports robust Q3 earnings, eyes market expansion

Natera (NTRA) delivered strong financial performance in Q3 2023, with raised revenue guidance and improved cash burn guidance.
The company's focus on achieving cash flow breakeven in 2024 while driving innovation and market engagement highlights a strategic growth trajectory.
While facing challenges such as pending lawsuits and regulatory uncertainties, Natera is well-positioned to capitalize on opportunities like market expansion and product innovation.

Natera reports robust earnings, eyes growth through strategic acquisitions

Natera's strong financial performance, strategic acquisitions, and focus on key developments position the company for continued growth.
While challenges like maintaining ASP trends and managing competition exist, opportunities in revenue growth, clinical studies, and guideline expansions offer potential upside.
Careful execution, volume growth, and momentum will be crucial for Natera's success in 2024, supported by confidence in their guidelines and innovative testing approaches.

Natera excels in Q1, eyes revenue growth and margin improvement

Natera's Q1 performance was outstanding, marked by revenue growth, margin expansion, and progress in key clinical areas.
While challenges like replicating exceptional performance and seasonal dips exist, the company is well-positioned for future growth.
Opportunities lie in improving margins, volume growth, and market penetration, supporting Natera's ambitious revenue targets.

Natera reports record-breaking Q3 earnings, poised for continued growth

Natera's Q3 2024 showcased exceptional financial performance, strong clinical advancements, and strategic debt management, positioning the company for sustained growth and innovation.
While facing challenges in community penetration and operational expenses, Natera's focus on innovation, customer service, and expanding clinical trials presents significant opportunities for future success.
With a clear focus on oncology patients, groundbreaking research, and upcoming data readouts, Natera remains poised for continued growth and leadership in the precision medicine space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

A Relative Strength Rating upgrade for Natera shows improving technical performance.

Natera Scores Relative Strength Rating Upgrade; Hits Key Benchmark

CollPlant Biotechnologies Ltd - ADR

Quest Diagnostics

DaVita

Novo Nordisk

ResMed

Zoetis

These healthcare stocks have great financials now, and in the future. They all represent the future of medicine, and offer big growth.

7 Healthcare Stocks Worth Your Time Now

Myriad Genetics

More babies are born in summer and early fall than other times of year, meaning mothers-to-be are likely undergoing prenatal testing now. Can investors profit?

Should You Buy These 2 Prenatal Testing Stocks?

Natera Inc. (NTRA) CEO Steve Chapman on Q4 2019 Results - Earnings Call Transcript

The stock is speculative but we think there is more upside on the market opportunity and near-term catalysts into 2020.

Natera Inc.: Multiple Catalysts In 2020 For More Upside

ACADIA Pharma

Arrowhead Pharmaceuticals

China Biologic Products Holdings

Galapagos

Spark Therapeutics

Zai Lab Ltd.

Many of these biotech companies are beating the Nasdaq Biotech Index. With cutting-edge therapies, these are great names to buy.

7 Exciting Biotech Stocks to Buy Now

Natera's (NTRA) CEO Steve Chapman on Q3 2019 Results - Earnings Call Transcript

Natera Inc. NTRA, +2.70% shares fell in the extended session Tuesday after the DNA test company announced a secondary offering of its stock.

Natera stock falls after hours on secondary-offering announcement

Natera (NTRA) is likely to maintain the current high on a number of favorable factors.

Natera (NTRA) Scales 52-Week High: What's Driving the Stock?

CEO of Natera Inc (30-Year Financial, Insider Trades) Steven Leonard Chapman (insider trades) sold 98,996 shares of NTRA on 08/09/2019 at an average price of $33 a share.

Natera Inc (NTRA) CEO Steven Leonard Chapman Sold $3.3 million of Shares

Natera's (NTRA) CEO Steve Chapman on Q2 2019 Results - Earnings Call Transcript

Investors are excited about two new products for the genetic testing and liquid biopsy developer.

Here's Why Natera Stock Soared 97.6% in the First Half of 2019

As of late, it has definitely been a great time to be an investor in Natera.

Natera, Inc.'s Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Natera, Inc. (NTRA).

Natera, Inc. (NTRA) Shares March Higher, Can It Continue?

Natera, Inc. (NTRA) CEO Steve Chapman on Q1 2019 Results - Earnings Call Transcript

The genetic testing leader announced full-year 2018 operating results, but the numbers were actually pretty poor.

News for Natera Stock (NTRA)